‘Screening Saves’ initiative launched to combat rising lung cancer rates
Less Is More With Advanced Surgical Approaches in Early-Stage NSCLC
“Historically, lobectomies were the standard surgical technique for patients with early-stage non–small cell lung cancer (NSCLC); however, more recently the NSCLC treatment paradigm shifted, as doing less surgery has demonstrated comparable outcomes, according to Alexis Chidi, MD, PhD, MSPH.”
BiTE Therapy Drug Tarlatamab Provides Improved Outcomes for Previously Treated Small Cell Lung Cancer
“The incidence of small cell lung cancer (SCLC) has significantly dropped in recent decades with the decline in cigarette smoking. Still, the aggressive nature and widespread metastases that characterize this disease continue to limit treatment success for those plagued by their diagnosis.”
Pennsylvania to Turn Turquoise for Lung Cancer Awareness During Turquoise Takeover
“The American Lung Association in Pennsylvania is turning the Commonwealth turquoise May 5-11, 2025, to raise awareness about lung cancer, honor those impacted and encourage residents to take action to help end the disease. The annual Lung Cancer Action Week and Turquoise Takeover celebration unites America to stand together to end lung cancer. Each year, the American Lung Association turns the nation turquoise—the signature color of LUNG FORCE—by illuminating buildings and landmarks across the U.S., encouraging the public to wear turquoise and share their support on social media and highlighting the stories of those impacted by lung cancer to inspire hope and save lives.”
The origin of a common form of lung cancer that affects above all the smokers are discovered
“Identify the cells which, if damaged by smoking, start carcinoma lesions with squamous cell lungs. The challenge of early diagnosis. The discovery of the cellular origin of one of the most common forms of lung cancer will help to refine early diagnosis and prevention of this disease, strongly associated with cigarette smoke.”
Immunotherapy: Balancing Cancer Treatment Benefits and Risks
“As with most cancer therapies in their early years, immunotherapy is celebrated for its many positive outcomes and also evaluated for its side effects, some of them difficult to manage. As immunotherapy has emerged as the fourth pillar of cancer treatment—alongside surgery, radiation, and chemotherapy—researchers at Yale Cancer Center are scrutinizing its toxicities and investigating ways to minimize risks and amplify benefits.”
First-Line Adagrasib Shows Activity in STK11-Mutant KRAS G12C NSCLC
“In this phase 2 cohort of the KRYSTAL-1 trial (NCT03785249), first-line adagrasib (Krazati) demonstrated a clinically meaningful objective response rate (ORR) of 30.3% (95% CI, 15.6%-48.7%) and a disease control rate of 66.7% in patients with advanced KRAS G12C-mutated non–small cell lung cancer (NSCLC) harboring concurrent STK11 mutations, according to findings presented at the 2025 AACR Annual Meeting .”
FDA-designated orphan drug could increase radiation efficacy in lung cancer
“DALLAS – April 30, 2025 – An FDA-designated orphan drug that can target a key vulnerability in lung cancer shows promise in improving the efficacy of radiation treatments in preclinical models, according to a study by UT Southwestern Medical Center researchers. The findings, published in Science Advances, suggest a new way to enhance the response to radiotherapy by inhibiting DNA repair in lung cancer cells.”
Anlotinib Combo Improves PFS/OS in Extensive-Stage Small Cell Lung Cancer
“Combining anlotinib and benmelstobart with chemotherapy significantly prolonged progression-free survival (PFS) and overall survival (OS) among patients with extensive-stage small cell lung cancer (ES-SCLC) across randomized clinical trials, according to findings from a network meta-analysis published in Translational Lung Cancer Research.”
Substantial Drop in Lung Cancer Deaths, Incidence, a Highlight of New Report on Cancer Statistics
“Erin Schenk, MD, PhD, says the National Cancer Institute’s 2025 Annual Report to the Nation captures advances in the detection and treatment of lung cancer.”
Adela Presents Data Demonstrating Ability of Tissue-Free MRD Test to Predict Recurrence in Lung Cancer at the American Association for Cancer Research Annual Meeting 2025
“FOSTER CITY, Calif., April 28, 2025 /PRNewswire/ — Adela, Inc., an innovator in blood testing for molecular residual disease (MRD) monitoring and early cancer detection through a proprietary genome-wide methylome enrichment technology, presented initial results demonstrating the ability of its MRD test to predict recurrence in early-stage non-small cell lung cancer, at the American Association for Cancer Research (AACR) Annual Meeting from April 25-30, 2025.”
